NAD+ biosynthetic pathways (Homo sapiens)
From WikiPathways
Description
NAD+ biosynthetic pathways. NAD+ levels are maintained by three independent pathways. First, the Preiss-Handler pathway uses dietary nicotinic acid and the enzyme nicotinic acid phosphoribosyltransferase (NAPRT) to generate NAMN, which is then transformed into NAAD by NAMN transferase (NMNAT). Three forms of this enzyme (NMNAT1, -2, and -3) have distinct subcellular localizations. The process is completed by the transformation of NAAD into NAD+ by NAD+ synthase (NADS). Second, the de novo synthesis pathway of NAD from tryptophan occurs through the kinurenine pathway (5). The first step in this pathway is the rate-limiting conversion of tryptophan to N-formylkinurenine (N-formylkin) by either IDO or TDO. Formylkinurenine is transformed into L-kinurenine (L-kin), 3-hydroxykinurenine, and 3-hydroxyanthranilic acid (3-HAA) and finally to ACMS. This compound can spontaneously condense and rearrange into quinolinic acid, which is transformed into NAMN, at which point it converges with the Preiss-Handler pathway. ACMS can also be decarboxylated into AMS by ACMS decarboxylase (ACMSD), leading to its oxidation into acetyl-CoA via the TCA cycle. Third, the NAD+ salvage pathway recycles the nicotinamide generated as a by-product of the enzymatic activities of NAD+-consuming enzymes: sirtuins, PARPs, and the cADPR synthases (CD38 and CD157). Initially, NAMPT recycles nicotinamide into NMN, which is then converted into NAD+ via the different NMNATs.
Quality Tags
Ontology Terms
Bibliography
- Verdin E; ''NAD� in aging, metabolism, and neurodegeneration.''; Science, 2015 PubMed Europe PMC Scholia
- Bogan KL, Brenner C; ''Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition.''; Annu Rev Nutr, 2008 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Name | Type | Database reference | Comment |
---|---|---|---|
3-HAA | Metabolite | HMDB01476 (HMDB) | |
ACMSD | GeneProduct | ENSG00000153086 (Ensembl) | |
ACMS | Metabolite | HMDB01330 (HMDB) | |
AMS | Metabolite | HMDB01330 (HMDB) | |
BST1 | GeneProduct | ENSG00000109743 (Ensembl) | |
CD38 | GeneProduct | ENSG00000004468 (Ensembl) | |
IDO1 | GeneProduct | ENSG00000131203 (Ensembl) | |
L-Kynurenine | Metabolite | HMDB00684 (HMDB) | |
N-Formylkin | Metabolite | HMDB01200 (HMDB) | |
NAD+ | Metabolite | HMDB00902 (HMDB) | |
NADH | Metabolite | HMDB01487 (HMDB) | |
NADSYN1 | GeneProduct | ENSG00000172890 (Ensembl) | |
NAMPT | GeneProduct | ENSG00000105835 (Ensembl) | |
NAPRT1 | GeneProduct | ENSG00000147813 (Ensembl) | |
NMNAT1 | GeneProduct | ENSG00000173614 (Ensembl) | |
Nicotinamide mononucleotide | Metabolite | 13553 (Chemspider) | |
Nicotinamide riboside | Metabolite | HMDB00855 (HMDB) | |
Nicotinamide | Metabolite | HMDB01406 (HMDB) | |
Nicotinic acid adenine dinucleotide | Metabolite | HMDB01179 (HMDB) | |
Nicotinic acid mononucleotide | Metabolite | HMDB01132 (HMDB) | |
Nicotinic acid | Metabolite | HMDB01488 (HMDB) | |
PARP1 | GeneProduct | ENSG00000143799 (Ensembl) | |
PARP2 | GeneProduct | ENSG00000129484 (Ensembl) | |
PARP4 | GeneProduct | ENSG00000102699 (Ensembl) | |
QPRT | GeneProduct | ENSG00000103485 (Ensembl) | |
Quinolinic acid | Metabolite | HMDB00232 (HMDB) | |
SIRT1 | GeneProduct | ENSG00000096717 (Ensembl) | |
SIRT2 | GeneProduct | ENSG00000068903 (Ensembl) | |
SIRT3 | GeneProduct | ENSG00000142082 (Ensembl) | |
SIRT4 | GeneProduct | ENSG00000089163 (Ensembl) | |
SIRT5 | GeneProduct | ENSG00000124523 (Ensembl) | |
SIRT6 | GeneProduct | ENSG00000077463 (Ensembl) | |
SIRT7 | GeneProduct | ENSG00000187531 (Ensembl) | |
TCA cycle | Pathway | ||
TDO2 | GeneProduct | 6999 (Entrez Gene) | |
TNKS2 | GeneProduct | ENSG00000107854 (Ensembl) | |
TNKS | GeneProduct | ENSG00000173273 (Ensembl) | |
Tryptophan | Metabolite | HMDB00929 (HMDB) |
Annotated Interactions
No annotated interactions